Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Dunlop

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
Current Opinion in Pharmacology|December 22, 2005
Glutamate-based therapeutic approaches: targeting the glutamate transport systemJohn Dunlop
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 17, 2008
Turning up the pace of ion channel screening in drug discoveryJohn Dunlop
Drug Discovery Today. Technologies|July 2, 2014
Identifying orphan G protein coupled receptors in drug discoveryJohn Dunlop, Richard M Eglen
Current Topics in Medicinal Chemistry|October 5, 2006
Ligands targeting the excitatory amino acid transporters (EAATs)John Dunlop, John A Butera
Current Topics in Medicinal Chemistry|February 20, 2010
Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's diseaseSimon N Haydar, John Dunlop
Journal of Psychopharmacology (Oxford, England)|January 15, 2015
Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?John Dunlop, Nicholas J Brandon
Neuropharmacology|June 5, 2007
Targeting the cholinergic system as a therapeutic strategy for the treatment of painPhilip G Jones, John Dunlop
Expert Opinion on Drug Discovery|March 19, 2013
Scintillation proximity assay in lead discoveryXavier Khawaja, John Dunlop, Dianne Kowal
Drug News & Perspectives|January 8, 2008
5-HT2C receptor agonists as an innovative approach for psychiatric disordersSharon Rosenzweig-Lipson, John Dunlop, Karen L Marquis
The Virtual Mentor : VM|December 20, 2012
The evangelizing patientJ Wesley Boyd, John Dunlop, Harold G Koenig
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
Current Opinion in Pharmacology|December 22, 2005
Glutamate-based therapeutic approaches: targeting the glutamate transport systemJohn Dunlop
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 17, 2008
Turning up the pace of ion channel screening in drug discoveryJohn Dunlop
Drug Discovery Today. Technologies|July 2, 2014
Identifying orphan G protein coupled receptors in drug discoveryJohn Dunlop, Richard M Eglen
Current Topics in Medicinal Chemistry|October 5, 2006
Ligands targeting the excitatory amino acid transporters (EAATs)John Dunlop, John A Butera
Current Topics in Medicinal Chemistry|February 20, 2010
Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's diseaseSimon N Haydar, John Dunlop
Journal of Psychopharmacology (Oxford, England)|January 15, 2015
Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?John Dunlop, Nicholas J Brandon
Neuropharmacology|June 5, 2007
Targeting the cholinergic system as a therapeutic strategy for the treatment of painPhilip G Jones, John Dunlop
Expert Opinion on Drug Discovery|March 19, 2013
Scintillation proximity assay in lead discoveryXavier Khawaja, John Dunlop, Dianne Kowal
Drug News & Perspectives|January 8, 2008
5-HT2C receptor agonists as an innovative approach for psychiatric disordersSharon Rosenzweig-Lipson, John Dunlop, Karen L Marquis
The Virtual Mentor : VM|December 20, 2012
The evangelizing patientJ Wesley Boyd, John Dunlop, Harold G Koenig
Pageof 10